

CUMULATIVE INDEX

VOLUME 24, NUMBERS 1-4, 1981

- Abdominal incisions, 1176-1180
- Abortion
 induced
 in adolescence, 982
 and genetic counselling, 1145-1146, 1158
 spontaneous
 and antenatal cytogenetic studies, 1033-1034
 in diabetic pregnancy, 150-151
- Abscess, pelvic, management of, 1187-1196
- Acetic acid, in vaginal secretions, 364-365
 in nonspecific vaginitis, 447
- Acetylcholinesterase in amniotic fluid, in
 neural tube defects, 1092-1100
- Acne, oral contraceptives affecting, 974, 992
- ACTH activity, in aging, 176
- Actinomycosis, pelvic inflammatory disease in,
 1236-1237
- Adenocarcinoma, vaginal, 506-507
 from DES exposure in utero, 386-388
- Adenosis, vaginal
 and carcinoma in situ, 495
 from DES exposure in utero, 381
- Adipose tissue metabolism, in pregnancy,
 22-26
- Adolescent contraception, 977-986
 abortion in, 982
 abstinence in, 980
 condoms and vaginal spermicidal agents in,
 981
 diaphragm in, 981-982
 and hazards of pregnancy, 979-980
 intrauterine device in, 982
 methods for, 980-985
 natural family planning in, 981
 oral contraceptives in, 982-985
 postcoital, 985
 and sex without intercourse, 980-981
 and sexuality in teenagers, 977-979
 withdrawal method in, 981
- Adrenal gland
 activity in menopause, 187-188
 androstenedione secretion in, 257
 congenital hyperplasia of, antenatal
 diagnosis of, 1046, 1049
 oral contraceptives affecting, 971
- Age
 maternal, and diabetes in pregnancy, 6-7
 of parents, and antenatal cytogenetic
 studies, 1025-1027, 1033
 and risks from oral contraceptives, 958-959
- Aging, 165-178
 bone loss in, 203-217
 cellular changes in, 166-167, 173
 and cross links between collagen fibrils,
 167-169
 endocrine system in, 175-177
 and Hayflick phenomenon, 167, 171
 immune system in, 171-172
 neuroendocrine system in, 169-171
 neurologic changes in, 177-178
 organ function in, 173-175
 and psychologic symptoms in menopause,
 220-221
 structural changes with, 173
 time-clock theory of, 169-171
- Albinism, prenatal diagnosis of, 1082
- Alcohol
 for labor suppression, affecting infant, 677
 in pregnancy, affecting fetus, 778, 858
- Alphaprodine in obstetric analgesia, affecting
 neonates, 652, 656
- Amenorrhea, from oral contraceptives, 889,
 915, 943-948
- Amino acids
 in amniotic fluid, 1045-1046
 in vaginal secretions, 357-359
- Amniocentesis, 1007-1018
 in diagnosis of cardiovascular disease,
 859, 861

- Amniocentesis (*Continued*)
 and Rh sensitization, 1013-1015
 risks of, 1011-1013
 technical aspects of, 1008-1011
 timing of, 1008-1009
 in twin pregnancies, 1016-1017
 and ultrasound examination, 1009,
 1015-1016, 1106-1108
- Amnion nodosum, in diabetic pregnancy, 153
- Amniotic fluid
 acetylcholinesterase in, in neural tube
 defects, 1092-1100
 amino acids in, 1045-1046
 analysis of cells in
 cultured cells, 1047-1050
 uncultured cells, 1047
 composition of, 1008
 creatinine in, 74-75
 cultures of, and cytogenetic interpretation,
 1023-1025
 fatty acids in, and fetal lung maturity, 86
 α -fetoprotein testing in, 1089-1102
 insulin in, in diabetic pregnancy, 96
 lecithin-sphingomyelin ratio in, 75-78,
 551-552
 mucopolysaccharides in, 1046
 phosphatidylcholine in, 86, 111
 phosphatidylglycerol in, 80-84, 136
 steroid hormones in, 1046
 thyroid hormones in, 1046
- Amphetamines in pregnancy, affecting fetus,
 858
- Ampicillin, in *Gardnerella vaginalis* infection, 455
- Analgesia and anesthesia, obstetric, 519-677
 caudal anesthesia in, 605-606
 effects on labor, 611-612
 neurologic complications from, 613
 effects on newborn, 630, 631-632, 649-667
 in high-risk pregnancy, 671-677
 long-term effects, 662-666
 short-term effects, 651-662
 epidural block in, 567, 603-605. *See also*
 Epidural analgesia in obstetrics
 and fetal and neonatal physiology, 545-552,
 635-637
 general anesthetics in, 561-565, 625-632.
See also General anesthesia for
 obstetrics
 in high-risk pregnancy, 671-677
 inhalation agents in, 563-565, 620-625.
See also Inhalation analgesia in
 obstetrics
 local anesthetics in, 565-568, 587-594, 602-
 616. *See also* Regional anesthesia
 in obstetrics
- Analgesia and anesthesia, obstetric,
 local anesthetic in, (*Continued*)
 maternal awareness in, 630
 and maternal physiology, 525-540
 muscle relaxants in, 568-571
 narcotics in, 597-600
 paracervical block in, 567, 588-591
 parenteral agents in, 561-563
 and pharmacology of anesthetics, 561-571
 placental transfer of drugs in, 555-558
 and preparation for childbirth, 575-585
 and prevention of perinatal asphyxia,
 671-673
 pudendal block in, 567, 592-594
 and resuscitation of newborn, 635-647
 selection of procedures in, 521-524
 spinal anesthesia in, 567, 602-603
- Androgens
 plasma levels in menopause, 184-188
 and postmenopausal fractures, 210, 214
 production in breast cancer, 310-311
- Androstenedione
 conversion to estrone, 189, 194, 257, 307
 plasma levels in aging women, 185-186
 secretion in menopause, 257
- Anemia
 Fanconi, antenatal diagnosis of, 1032, 1082
 hemolytic, antenatal diagnosis of, 1064-1066
 iron deficiency, oral contraceptives af-
 fecting, 973, 990
 megaloblastic, from oral contraceptives, 973
 sickle cell. *See* Sickle cell disease
- Anencephaly
 and face presentations, 333-334
 and α -fetoprotein in amniotic fluid, 1089-
 1091
 in infants of diabetic mothers, 152
 ultrasonic diagnosis of, antenatal, 1110
- Anesthesia, obstetric. *See* Analgesia and
 anesthesia, obstetric
- Angina pectoris, in pregnancy, 785
- Antenatal diagnosis of disorders
 in adrenal hyperplasia, congenital, 1046,
 1049
 in albinism, 1082
 amniocentesis in, 1007-1018. *See also*
 Amniocentesis
 amniotic fluid cells in
 cultured, 1047-1050
 uncultured, 1047
 in argininosuccinicaciduria, 1045
 in ataxia-telangiectasia, 1081
 in Bloom's syndrome, 1032, 1081
 in cardiovascular disorders, 859, 861
 in Chediak-Higashi syndrome, 1083

Antenatal diagnosis of disorders (Continued)

and confidentiality of family studies, 1143-1144, 1156

in Conradi-Hunerman syndrome, 1083

controversial requests for, 1143, 1160

in cutis laxa, 1085

in cystic fibrosis, 1046-1047

in cystinosis, 1048

in cytogenetic abnormalities, 1023-1037.

See also Cytogenetic studies, antenatal

DNA analysis in, 1049-1050, 1056-1058

in ectodermal dysplasia, hypohidrotic, 1084

in Ehlers-Danlos syndrome, 1085

in epidermolysis bullosa, 1075-1077, 1085, 1086

in epidermolytic hyperkeratosis, 1077-1079

ethical issues in, 1151-1166

in Fabry's disease, 1084

in Fanconi's anemia, 1082

fetal blood sampling in, 1050-1051, 1058-1061

fetal skin sampling in, 1072-1079

α -fetoprotein testing in

in amniotic fluid, 1089-1102

in maternal serum, 1099-1100, 1103-1106, 1121-1131

and ultrasound examination, 1103-1106

fetoscopy in, 1069-1072

in fucosidosis, 1084

in glutaric acidemia, 1045

in hemoglobinopathies, 1050, 1055-1062

in hemolytic anemias, 1064-1066

in hemophilias, 1062-1064

in Hunter's syndrome, 1049

in ichthyosis, 1072-1075, 1080, 1084

and informed consent of screenees, 1137, 1154-1156

and legal liability in genetic screening, 1133-1147

in Menkes syndrome, 1080

in metabolic disorders, 1041-1051

in methylmalonic acidemia, 1045

in mucopolysaccharidoses, 1046, 1048

in Netherton syndrome, 1083

in neural tube defects, 1089-1102

in phenylketonuria, 1045-1046

in Pompe's disease, 1047, 1049

and problems with abortion, 1145-1146, 1158

in Refsum's disease, 1084

review questions on, 1169-1171

risks of techniques in, 1139, 1158-1160

in Sjogren-Larsson syndrome, 1080

in skin disorders, hereditary, 1069-1086

Antenatal diagnosis of disorders (Continued)

in Tay-Sachs disease, 1047, 1049

in thyroid disease, 1046

in trichothiodystrophy, 1083

in tuberous sclerosis, 1086

ultrasound in, 1093, 1103-1120

with amniocentesis, 1009, 1015-1016, 1106-1108

in Wiskott-Aldrich syndrome, 1082

in xeroderma pigmentosum, 1081

Antiarrhythmic drugs, in pregnancy, 809-813

Anticholinergic agents, in obstetric analgesia, 571

Anticoagulant drugs, in pregnancy, 813-816, 826

in pulmonary embolism, 770

in venous thrombosis, 766-767

Anticonvulsants in pregnancy, affecting fetus, 839, 858

Antidiuretic hormone, activity in aging, 176

Aortia, coarctation in pregnancy, 730

Aortic valve

bicuspid, in pregnancy, 728-729

regurgitation in pregnancy, 729

stenosis in pregnancy, 727-728, 780

Apgar scores

anesthesia affecting, 631

and face presentations, 343

and resuscitation of newborn, 640-643

Argininosuccinicaciduria, antenatal diagnosis of, 1045

Arrhythmias

diagnosis and management of, 803-805

fetal, 839-841

in pregnancy, 782-783

cardioversion in, 809-813

disopyramide in, 812

procainamide in, 811

propranolol in, 812-813, 858

quinidine in, 811

treatment of, 809-813

Arteritis in pregnancy, 829

Arthritis, rheumatoid, oral contraceptives affecting, 970

Ascites, and fetal arrhythmias, 841

Asphyxia, perinatal, 671-673

in infants of diabetic mothers, 135

Aspiration

in general anesthesia, 629

meconium, 646-647

Ataxia-telangiectasia, prenatal diagnosis of, 1081

Atherosclerosis, and protective effect of estrogen therapy, 272-275

Atrial septal defect, in pregnancy, 732-734

- Atropine, in obstetric analgesia, 571
- Bacterial flora, vaginal, 360-361, 369, 446
- Barbiturates
in obstetric analgesia, 561-562, 598
effects on neonates, 651, 652, 653
and perinatal asphyxia prevention, 672
- Behavior of neonates, obstetric anesthesia affecting, 631-632, 649-667
- Bicarbonate therapy, in resuscitation of newborn, 644
- Bilirubin, and hyperbilirubinemia in infants of diabetic mothers, 133
- Biopsy, endometrial, 290-292, 295-296
- Birth weight
and brow presentations, 344
and face presentations, 336
- Bladder, operative injuries of, 1275-1276
- Blood flow
fetal, 545-548, 635-636
drugs affecting, 672
ultrasonographic evaluation of, 842-847
regional, in pregnancy, 533
renal, 533, 539
uterine, 530-533, 556
- Blood pressure in pregnancy, 529, 699. *See also* Hypertension; Hypotension
- Blood volume in pregnancy, 526, 693-697
- Bloom's syndrome, antenatal diagnosis of, 1032, 1081
- Bone conditions. *See* Skeletal system
- Brain
changes in aging, 177-178
development of
corticosteroids affecting, 138
in infants of diabetic mothers, 152
- Breast
cancer of
and age at first pregnancy, 302
androgen production in, 310-311
anti-estrogen therapy in, 314
and binding capacity of sex hormone-binding globulin, 308-310
and delayed menopause, 303
and dietary fat intake, 303
epidemiologic and biochemical studies in, 302-306
estriol levels in, 304-305
estrogen receptors in, 313
from estrogen therapy, 314-315
estrone production in, 307
in hypothyroidism, 311-312
in males, estrogen-induced, 304
ovarian hormones in genesis of, 303-304
postmenopausal, estrogen therapy in, 314
progesterone receptors in, 313
- Breast, cancer of (*Continued*)
prolactin levels in, 311
radiation-induced, 306
and tryptophan metabolites in urine, 307
development of, hormonal factors in, 301-302
disease from oral contraceptives, 907-913
- Breech delivery, analgesia and anesthesia in, 523
- Brow presentations, 343-349
course of labor in, 346-347
diagnosis of, 345-346
etiology of, 343-345
management of, 347-348
and perinatal mortality or morbidity, 348
- Budd-Chiari syndrome, from oral contraceptives, 957
- Bupivacaine, in obstetric analgesia, 567-568, 604
effects on neonates, 657-658, 662
toxic reactions to, 608
- Cadaverine, in vaginal discharge, 448, 449
- Calcitonin levels, in infants of diabetic mothers, 131
- Calcium
excretion affected by estrogen, 210
hypocalcemia in infants of diabetic mothers, 130-133
in osteoporosis prevention, 214, 216
- Candidiasis, vulvar and vaginal, 424-430
clinical features of, 424-425
diagnosis of, 425-427
treatment of, 427-450, 437
- Carbocaine, in obstetric analgesia, affecting neonates, 656
- Carbohydrates
metabolism in diabetic pregnancy, 59-60
in vaginal secretions, 359-360
- Carcinoma. *See* Tumors
- Cardiac output
factors affecting, 791-795
fetal, 556
in pregnancy, 526-529, 697-699
distribution of, 702-703
exercise affecting, 705-706
- Cardiomegaly, in pregnancy, 737
- Cardiomyopathy
in infants of diabetic mothers, 139
in pregnancy, 737, 781, 826-827
- Cardiopathy, in diabetic pregnancy, 114-116
- Cardiovascular disorders
anomalies in infants of diabetic mothers, 153
fetal
arrhythmias, 839-841
in chromosomal disorders, 859

Cardiovascular disorders, fetal (Continued)

- diagnosis of, 859-861
- familial predisposition to, 838, 852-853
- maternal disease as factor in, 153, 839
- and maternal drug ingestion, 839, 853-854, 857-858

- in mendelian disorders, 859-860
- multifactorial inheritance of, 851-857
- recurrence risk in, 855-856
- teratogens causing, 857-859
- ultrasonographic evaluation of, 837-847

in pregnancy, 691-865

- acquired lesions in, 780-782
- activity recommendations in, 777
- antiarrhythmic drugs in, 809-813
- anticoagulant drugs in, 813-816, 826
- classification of, 774-776
- congenital heart disease, 780
- counseling in, 776-777
- diet recommendations in, 777
- digitalis glycosides in, 817-818
- diuretics in, 818-820
- evaluation of specific problems in, 722-740

- general anesthesia in, 628
- guidelines in management of, 773-786
- health priorities in, 776
- and hemodynamic monitoring, 795-797
- and hemodynamic physiology, 789-795
- and hemodynamic therapeutic options, 797-805

- infection control in, 777
- intrapartum management of, 789-806
- and maternal physiology, 693-707
- medications affecting, 778, 785
- and noninvasive assessment of function, 711-722

- question-related approach to, 778-779
- regional anesthesia in, 615-616
- review questions on, 863-865
- symptoms and signs of, 773-774
- therapeutic agents in, 809-820
- venous disorders in, 749-759
- venous dynamics in, 743-749

Cardiovascular system

- fetal, 545-548, 635-636

- in pregnancy, 525-533

Cardioversion in arrhythmias, in pregnancy, 809-811

Carotid pulse tracings, in pregnancy, 712-714

Catecholamines

- estrogen interaction with, 224-226, 235
- and hot flashes in menopause, 232, 235-237
- and psychologic symptoms in menopause, 222-226

Catecholamines (Continued)

- urinary, in infants of diabetic mothers, 127

Caudal anesthesia in obstetrics, 605-606

- effects on labor, 611-612

- neurologic complications from, 613

Caudal dysplasia, in infants of diabetic mothers, 151-159

Cellular changes in aging, 166-167, 173

Cellular desquamate, from vaginal epithelium, 357

Central nervous system. *See also* Brain

- anomalies in infants of diabetic mothers, 152
- oral contraceptives affecting, 966-970

Cephalopelvic disproportion

- and brow presentations, 344

- and face presentations, 336

Cerebral vein thrombosis, in pregnancy, 830-831

Cerebrovascular disease

- development after estrogen therapy, 276
- from oral contraceptives, 896, 955-956

in pregnancy, 825-832

- arteritis in, 829

- atrial fibrillation in, 826

- cardiomyopathy in, 826-827

- in choriocarcinoma, 830

- in endocarditis, 828

- hypotension in, 827

- mitral valve prolapse in, 827

- paradoxical embolism in, 828

- in sickle cell disease, 829

- subarachnoid hemorrhage in, 832

- thrombosis of cerebral vein in, 830-831

- thrombotic thrombocytopenic purpura in, 829-830

Cervical mucus

- in mucorrhea, 430-432, 437

- properties of, 356-357

Cervicitis, 420-424

- clinical features of, 420-423

- treatment of, 423-424, 437

Cervix uteri

- abnormalities from DES exposure in utero, 831

carcinoma of

- hysterectomy in, 1251-1252

- postmenopausal bleeding in, 286, 287

- changes from oral contraceptives, 918-922

Cesarean section

- and anesthetic agents affecting neonates, 658-659, 660, 661, 662

Cesarean section

- and anesthetic agents affecting neonates, 658-659, 660, 661, 662

- in diabetic pregnancy, 103

- Cesarean section, in
 diabetic pregnancy (*Continued*)
 and control of glucose levels, 60-62, 96
 with nephropathy, 112
 and respiratory distress syndrome in
 infants, 136-138
 effects on neonates, 675-676
 general anesthesia in, 626-627
 maternal hemodynamics during, 701-702
 spinal anesthesia in, 603
- Chediak-Higashi syndrome, prenatal
 diagnosis of, 1083
- Chemotherapy, and antenatal diagnosis of
 fetal disorders, 1034
- Cherney incision, 1179-1180
- Chest x-ray in pregnancy, 712
- Chlamydia trachomatis*
 cervicitis from, 420, 437
 and pelvic inflammatory disease, 1235-1236
- Chloasma, from oral contraceptives, 973-974
- Chloroprocaine, in obstetric analgesia,
 567-568, 604
 effects on neonates, 661, 662
 toxic reactions to, 608
- Cholesterol
 metabolism in pregnancy, 35-38
 oral contraceptives affecting levels of, 934
- Chondrodysplasia puncta, prenatal diagnosis
 of, 1083
- Choriocarcinoma
 cerebral metastases in, 830
 oral contraceptives affecting, 923
- Chorionic cells, fetal, in maternal cervical
 canal, 1036
- Chromatography
 in nonspecific vaginitis, 447-448
 of odoriferous constituents of vaginal
 fluids, 363
 two-dimensional, for fetal lung maturity,
 80, 82
- Chromosome abnormalities
 antenatal diagnosis of, 1023-1037
 cardiovascular anomalies in, 859
- Circadian rhythms, 170
 for androstenedione, 185
 for dehydroepiandrosterone, 187
 for testosterone, 186
- Circulation. *See* Blood flow
- Cleft lip or palate, in infants of diabetic
 mothers, 153
- Climacteric
 female, 253. *See also* Menopause
 in males, 176-177
- Clomiphene, in breast cancer, 314
- Clonidine, in menopausal hot flashes, 238
- Clotrimazole, in candidal vulvovaginitis,
 427-430, 437
- Coarctation of aorta, in pregnancy, 730
- Collagen, cross links between fibrils of, in
 aging, 167-169
- Colposcopy, in condylomata acuminata,
 465-466
- Conduction anesthesia in obstetrics. *See*
 Regional anesthesia in obstetrics
- Condylomata acuminata, vaginal, 461-481
 clinical significance of, 475-479
 colposcopy in, 465-466
 cytology of, 462-463
 differential diagnosis of, 489
 electron microscopy of, 467-475
 epidemiology of, 461-462
 histology of, 463-465
 in pregnancy, 481
 treatment of, 479-481
- Congenital anomalies, in infants of diabetic
 mothers, 42-44, 140-141,
 149-156
- Connective tissue disease, oral contraceptives
 affecting, 970-971
- Conradi-Hunerman syndrome, prenatal
 diagnosis of, 1083
- Contraceptives
 intrauterine
 for adolescents, 982
 and *Gardnerella vaginalis* infection, 457
 oral, 867-996. *See also* Oral contraceptives
- Contraction stress test, in diabetic
 pregnancy, 99
- Corneal sensitivity, oral contraceptives
 affecting, 970
- Coronary artery disease
 development after estrogen therapy, 276
 in diabetic pregnancy, 114-116
- Coronary thrombosis, from oral contra-
 ceptives, 953-955
- Corticosteroids
 in provocative tests for glucose intolerance,
 14-15
 therapy in pregnancy
 and brain development in infants, 138
 and fetal lung maturity, 102, 138-139
- Cortisol
 and breast development, 302
 excretion affected by estrogen, 210-212
 plasma levels in infants of diabetic mothers,
 128
- Cortisone provocative test, for glucose
 intolerance in pregnancy, 14-15
- Corynebacterium vaginale*. *See* *Gardnerella*
 vaginalis infection

- Counselling
in diabetes, 156-157
genetic, 1145-1146, 1158
- Creatinine
in amniotic fluid, 74-75
clearance of
aging affecting, 174
in diabetic nephropathy in pregnancy, 110
- Curare, hypotension from, 570
- Cutis laxa, prenatal diagnosis of, 1085
- Cystic fibrosis, antenatal diagnosis of, 1046-1047
- Cystinosis, antenatal diagnosis of, 1048
- Cytogenetic studies, antenatal, 1023-1037
indications for, 1025-1036
age of parents, 1025-1027, 1033
chromosomal breakage syndromes, 1032
chromosomal inversions, 1030-1032
chromosomal translocations, 1028-1030
chromosomal variants in parents, 1035
delayed fertilization or ovulation, 1035
exposure to radiation or chemotherapy, 1034
fetal growth retardation, 1035-1036
metabolic derangements in parents, 1034
previous child with autosomal trisomy, 1027-1028
previous stillborn or spontaneous abortuses, 1033-1034
X-linked recessive disorders, 1032
- Cytology
in condylomata acuminata, 462-463
in postmenopausal bleeding, 289-290
- Dehydroepiandrosterone levels, in menopause, 187-188
- Delivery
in brow presentations, 347-348
in diabetic pregnancy, 101-103
with nephropathy, 111-112
in face presentations, 338-339
hemodynamics in, 700-702
- Depression
and effects of oral contraceptives, 889-890, 966
postmenopausal, estrogen therapy in, 226
- Diabetes risk, with oral contraceptives, 930-932
- Diabetic pregnancy, 1-162, 675
affecting fetus, 839, 858
carbohydrate metabolism in, 59-60
cardiopathy in, 114-116
classification of, 4, 107
counseling in, 156-157
delivery in
method of, 103
- Diabetic pregnancy, delivery in (*Continued*)
in nephropathy, 111-112
regional anesthesia for, 615
timing of, 101-102
and detection of glucose intolerance, 10-16
clinical protocol for, 15-16
diagnosis of, 3-17
diet in, 56-57, 96
estriol assays in, 98-99
and fall in insulin requirements, 98
family history in, 6
fetal assessment in, 73-87, 97-100. *See also* Fetus, maturity tests
contraction stress test in, 99
and maternal assessment of fetal activity, 100
nonstress test in, 99-100
fetal lung development in, 84-86
gestational diabetes, 3-17
glucose levels in, 13, 54-56
glycohemoglobins in, 65-71, 96
glycosuria in, 5-6
hospitalization versus outpatient care in, 100-101
hydramnios in, 98, 153
and infants of diabetic mothers, 125-142.
See also Infants of diabetic mothers
insulin secretion in, 39-40
insulin therapy in, 57-58, 95-96
ketoacidosis in, 60
treatment of, 62-63, 97
lecithin-sphingomyelin ratio in, 79-80
management of, 91-103
and maternal age, 6-7
maternal fuel metabolism in, 40-41
metabolic changes in, 38-44
metabolic control of, 51-63
definition of, 52-56
in intrapartum period, 60-62, 96-97
objectives of, 58-59
mortality in
maternal, 91-92
perinatal, 92-93, 150-151
nephropathy in, 107-114
delivery in, 111-112
fetal evaluation in, 111
neonatal complications in, 112-113
postdelivery follow-up in, 113
treatment of, 110
nocturnal hypoglycemia in, 60, 94, 128
pyelonephritis in, 98
and regulation of maternal blood glucose, 54-56, 93-97
after renal transplantation, 114

- Diabetic pregnancy (*Continued*)
 retinopathy with, 116-121
 nephropathy with, 110
 treatment of, 117-121
 review questions on, 161-162
 risk factors for, 4-10
 and screening for glucose tolerance, 7-10, 32
 stages of, 3-4
 teratogenic risk in, 42-44, 140-141, 149-156
 vascular disease in, 107-121
 weight changes in, 38-39
- Diazepam, in obstetric analgesia, 599
 effects on neonates, 657, 659
- Diet
 in diabetic pregnancy, 56-57, 96
 fat intake as risk factor in breast cancer, 303
- Diethylstilbestrol exposure in utero
 cervical abnormalities from, 381
 and evaluation of offspring, 388-391
 uterine abnormalities from, 381-386
 vaginal lesions from, 379-383
 adenocarcinoma, 386-388
 benign abnormalities, 381
 embryologic aspects of, 381
 and treatment of offspring, 392-393
- Digitalis glycosides, in pregnancy, 817-818
- Discharge, vaginal
 causes of, 407-408
 mucoid or epithelial, 430-432
- Disopyramide, in arrhythmias in pregnancy, 812
- Diuretics, in pregnancy, 818-820
 in diabetic nephropathy, 110
- DNA analysis, in amniotic fluid cells, 1049-1050, 1056-1058
- DNCB therapy, in vaginal carcinoma in situ, 494
- L-Dopa, effects on aging, 170, 220-221
- Dopamine
 metabolism affected by estrogen, 224-225
 as neurotransmitter, 222
- Down's syndrome, antenatal diagnosis of, 1025-1029
- Drugs
 cardiovascular agents in pregnancy with
 heart disease, 809-820
 effects in pregnancy with heart disease, 778, 785
 maternal ingestion of, fetal reaction to, 839, 853-854, 857-858
 metabolism in aging, 175
 oral contraceptive agents. *See* Oral contraceptives
 teratogenic effects of, 155-156
- Ductus arteriosus patency, in pregnancy, 735
- Dyskeratocytes, in condylomata acuminata, 463, 469
- Dysmenorrhea, oral contraceptives in, 990-992
- Dysplasia
 caudal, in infants of diabetic mothers, 151-152
 ectodermal hypohidrotic, prenatal diagnosis of, 1084
- Echocardiography
 fetal, 837-842
 indications for, 838-841
 technique of, 841-842
 in pregnancy, 714-718, 786
- Ectodermal dysplasia, hypohidrotic, prenatal diagnosis of, 1084
- Education for childbirth, 575-585. *See also* Prepared childbirth
- Ehlers-Danlos syndrome
 collagen in, 169
 prenatal diagnosis of, 1085
- Eisenmenger syndrome, in pregnancy, 732
- Electrocardiography, in pregnancy, 712, 786
- Embolism
 paradoxical, in pregnancy, 828
 in pregnancy, 784
 pulmonary
 from oral contraceptives, 952
 in pregnancy, 762, 769-770
- Encephalocoele, and α -fetoprotein in amniotic fluid, 1091
- Endocarditis, subacute bacterial, in pregnancy, 734-735, 784, 828
- Endocrine system
 aging affecting, 175-177
 disorders of
 oral contraceptives affecting, 971-972
 and psychologic symptoms in menopause, 221-227
- Endodermal sinus tumors, vaginal, 507
- Endometriosis
 hysterectomy in, 1251
 vaginal, 495
- Endometrium
 atrophy of, postmenopausal bleeding in, 286, 287
 biopsy of, 290-292, 295-296
 carcinoma of
 cytologic studies in, 290
 estrogen role in, 197-200, 213, 243-249, 275-276
 hysterectomy in, 1252
 management of, 296
 postmenopausal bleeding in, 286, 287

Endometrium (Continued)

- estrogen in, 197-200
- hyperplasia of
 - and breast cancer, 312
 - cytologic studies in, 290
 - management of, 296-297
 - oral contraceptives affecting, 917, 990
 - postmenopausal bleeding in, 286, 287, 293-294
- oral contraceptives affecting, 874-875
- polyps of, postmenopausal bleeding in, 292, 296
 - management of, 297
- tumors from oral contraceptives, 915-918

Enflurane, in obstetric anesthesia, 564-565, 623

Environmental factors in congenital heart disease, 851-857

Enzymes

- in amniotic fluid cells, 1047-1048
- defects in fetal erythrocytes, diagnosis of, 1065-1066

Epidermolysis bullosa, antenatal diagnosis of, 1075-1077, 1085, 1086

Epidermolytic hyperkeratosis, antenatal diagnosis of, 1077-1079

Epidural analgesia in obstetrics, 567, 603-605

- catheter complications with, 611
- effects on labor, 611
- effects on neonates, 655, 656, 657-660, 661, 662
- failure of, 609-611
- neurologic complications from, 613

Epilepsy

- maternal, affecting fetus, 839
- oral contraceptives affecting, 969

Epinephrine, in resuscitation of newborn, 645

Erythema

- multiforme, oral contraceptives affecting, 971
- nodosum, oral contraceptives affecting, 971

Estradiol

- conversion from testosterone, 189, 194
- plasma levels
 - aging affecting, 181-182
 - in breast cancer, 305
 - postmenopausal, 188-189, 256-257
 - postmenopausal production of, 307

Estriol levels

- in breast cancer, 304-305
- in diabetic pregnancy, 98-99
- with nephropathy, 111

Estrogen

- affecting vaginal epithelium, 360
- anti-estrogen therapy in breast cancer, 314

Estrogen (Continued)

- and breast development, 301-302
- deficiency of
 - and hot flashes in menopause, 231-237
 - and loss of bone density, 203-217
 - and psychologic symptoms in menopause, 219-227

and endometrial cancer development, 197-200, 213, 243-249, 275-276

- biologic plausibility of, 243-244
- epidemiologic studies of, 245-248
- incidence of, 244-245

in endometrium, 197-200

extraglandular formation of, 190, 193-197, 244, 306

- increased, clinical conditions with, 196-197

interaction with catecholamines, 224-226, 235

in oral contraceptives. *See* Oral contraceptives

plasma levels in menopause, 188-190

postmenopausal secretion of, 193-200

production and transport of, 306-310

and psychologic symptoms in menopause, 226-227

receptor activity, 198-199, 200

- in breast cancer, 313

therapy with

- advantages and benefits of, 266-275
- in atherosclerosis prevention, 272-275
- in atrophic genitourinary cancer, 267-269, 433-434

- in bone loss prevention, 205-217, 269-272
- and breast cancer development, 314-315
- disadvantages and risks of, 275-277
- dosage in, 277

- in dysfunctional uterine bleeding, 275
- in hot flashes, menopausal, 237-238, 266-267

- in menopause, 253-280

- in postmenopausal breast cancer, 314
- in postmenopausal depression, 226
- progestins with, 213-216, 248
- recommendations for use of, 277-280
- thromboembolism from, 276-277

Estrone

- conversion from androstenedione, 189, 194, 257, 307
- postmenopausal production of, 189, 257, 307

Ethical issues, in genetic screening and antenatal diagnosis, 1151-1166

Etidocaine, in obstetric anesthesia, 568

effects on neonates, 662

- Exercise, in pregnancy, 704-707
and fetal health, 706-707
- Eyes
oral contraceptives affecting, 956, 970
retinopathy in diabetic pregnancy, 116-121
- Fabry's disease, prenatal diagnosis of, 1084
- Face presentations, 333-343
course of labor in, 338-339
diagnosis of, 337-338
etiology of, 333-337
management of, 339-341
and perinatal mortality or morbidity, 341-343
- Fallopian tubes, oral contraceptives affecting, 873-874
- Fallot tetralogy, in pregnancy, 732
- Fanconi's anemia, antenatal diagnosis of, 1032, 1082
- Fat
intake as risk factor in breast cancer, 303
mobilization in pregnancy, 34-35
storage in pregnancy, 22-26
in diabetic pregnancy, 38-39
- Fatty acids in amniotic fluid, and fetal lung maturity, 86
- Fertilization, delayed, and chromosomal abnormalities, 1035
- Fetal cells, lipid staining of, as fetal maturity test, 74
- α -Fetoprotein
in amniotic fluid, 1089-1102
in maternal serum, 1099-1100, 1103-1106, 1121-1131
- Fetoscopy, 1069-1072
risks of, 1071
and skin sampling, 1072-1079
- Fetus
antenatal diagnosis of disorders in. *See* Antenatal diagnosis of disorders
arrhythmias in, 839-841
blood sampling for diagnosis of disorders, 1050-1051, 1058-1061
cardiovascular system in, 545-548, 635-636
disorders of. *See* Cardiovascular disorders, fetal
distressed, and regional anesthesia use, 614
face and brow presentations of, 333-349
growth retardation of
and antenatal chromosome studies, 1035-1036
in diabetic nephropathy, 111
infants of diabetic mothers. *See* Infants of diabetic mothers
lung development in
corticosteroids affecting, 102, 138-139
- Fetus, lung development in (*Continued*)
in diabetic pregnancy, 84-86
macrosomia in diabetic pregnancy, 41-42, 94, 139-140
maternal drug ingestion affecting, 839, 853-854, 857-858
maternal exercise affecting, 706-707
maturity tests
creatinine in amniotic fluid, 74-75
in diabetic nephropathy, 111
in diabetic pregnancy, 73-87, 97-110
fatty acid analysis, 86
lecithin-sphingomyelin ratio in amniotic fluid, 75-78, 111, 136
lipid staining of fetal cells, 74
new assays in, 86-87
phosphatidylcholine in amniotic fluid, 86, 111
phosphatidylglycerol in amniotic fluid, 80-84, 136
rapid surfactant test, 78-79
roentgenography, 74
two-dimensional chromatography, 80, 82
ultrasonography, 75, 100
physiology of, 545-552, 635-637
pulmonary function in, 549-552, 636-637
skin sampling in, 1072-1079
ultrasonography of
for cardiac anatomy, 837-842
for vascular dynamics, 842-847
- Fibroblasts, fetal, in antenatal diagnosis of disorders, 1047-1048, 1057
- Fistulas, vaginal, 408
- Fluid balance, maternal, and neonatal problems, 674
- Fluoride therapy, effects in postmenopausal women, 214
- 5-Fluorouracil, in vaginal carcinoma in situ, 492-494
- Foam test for fetal maturity, 78
- Follicle-stimulating hormone levels
aging affecting, 181-182
in menopausal hot flashes, 233
oophorectomy affecting, 232
postmenopausal, 254-256
- Forceps delivery, analgesia and anesthesia in, 523
- Fractures, postmenopausal
after androgen therapy, 210
prevention with estrogen therapy, 207-209, 214, 269-272
- Fucosidosis, prenatal diagnosis of, 1084
- Gallamine, in obstetric anesthesia, 570
- Gardnerella vaginalis* infection, 374, 407, 411-412, 439-458

Gardnerella vaginalis infection (Continued)

- and amines in vaginal discharge, 448
- clinical diagnosis of, 451-454
- clue cells in, 450-451
- and concomitant organisms, 445-448
- culture isolation of bacteria in, 442-443
- invasiveness of, 456-457
- male role in, 456
- prevalence of, 443-445
- symptoms and signs of, 449
- treatment of, 374, 411, 437, 454-456
- trichomonas infection with, 455-456
- vaginal odor in, 374, 411, 445, 448, 450

Gastrointestinal tract

- anomalies in infants of diabetic mothers, 153
- changes in pregnancy, 538-539
- oral contraceptives affecting disorders in, 972
- ultrasonic diagnosis of anomalies in, antenatal, 1114-1116

Gastroschisis, ultrasonic diagnosis of, antenatal, 1115

General anesthesia for obstetrics, 561-565, 625-632

- aspiration risk in, 629
- in cesarean section, 626-627
- effects on neonates, 655
- maternal ventilation in, 629-630
- in prematurity, 629
- uterine relaxation from, 627
- in vaginal delivery, 625-626

Genetic disorders, antenatal diagnosis of. *See* Antenatal diagnosis of disorders

Genetic factors

- in congenital heart disease, 851-857
- in malformations in children of diabetic parents, 154

Genitourinary tract

- atrophic changes in menopause, estrogen therapy in, 267-269
- malformations in infants of diabetic mothers, 153

Gestational diabetes, 3-17

Glomerulosclerosis, in diabetic pregnancy, 108

Glucagon

- plasma levels in infants of diabetic mothers, 128
- secretion in pregnancy, 31-32

Glucose

- assimilation in pregnancy, 32-34
- excretion in pregnancy, 539
- hyperglycemia as cause of congenital malformations, 155
- hypoglycemia
 - as cause of congenital malformations, 155

Glucose, hypoglycemia (Continued)

- in infants of diabetic mothers, 125-130
- nocturnal, in diabetic pregnancy, 60, 94, 128
- maternal levels of, affecting infant, 674-675
- metabolism affected by oral contraceptives, 927-932
- plasma levels in diabetic pregnancy, 54-56
- regulation of, 54-56, 93-97
- tolerance tests
 - aging affecting, 177
 - and detection of intolerance in pregnancy, 10-16
 - in gestational diabetes, 3-4
 - and glycosuria in pregnancy, 5-6
 - intravenous, 13-14
 - oral, 12-13
 - risk factors for, 5
 - as screening test in pregnancy, 7-10, 32
 - and single blood glucose levels, 10-11
 - and steroid provocative tests, 14-15

Glutaric acidemia, antenatal diagnosis of, 1045

Glycogen, vaginal, 360, 369

Glycohemoglobins, in diabetic pregnancy, 65-71, 96

Glycopyrrolate, in obstetric analgesia, 571

Glycosuria in pregnancy, and gestational diabetes, 5-6

Gonadotropin releasing hormone, response to, in amenorrhea, 946-947

Gonorrhea, cervicitis in, 420, 437

Gracilis muscle flap transposition, 1280-1282

Growth hormone

- and breast development, 302
- plasma levels in infants of diabetic mothers, 128

Growth retardation, intrauterine

- and antenatal chromosome studies, 1035-1036
- in diabetic nephropathy, 111

Haemophilus vaginalis. *See* *Gardnerella vaginalis* infection

Halothane, in obstetric anesthesia, 564-565, 623

Harlequin ichthyosis, antenatal diagnosis of, 1072-1075

Hayflick phenomenon, in aging, 167, 171

Headaches

- oral contraceptives affecting, 968-969
- from regional anesthesia, 607

Heart

- cardiomyopathy in infants of diabetic mothers, 139

Heart (*Continued*)

- congenital disease of. *See* Cardiovascular disease, fetal
- diabetic cardiopathy in pregnancy, 114-116
- disease in pregnancy, 691-865. *See also* Cardiovascular disease, in pregnancy
- failure in pregnancy, 783-784
- fetal
 - development of, 547, 635
 - ultrasonography of, 837-842
- myocardial infarction
 - in diabetic pregnancy, 114-116
 - from oral contraceptives, 896-897
 - and protective effect of estrogen therapy, 272-275
- in pregnancy, 525-526
- Heat loss in neonates, 638
- Hematocrit, in infants of diabetic mothers, 134
- Hematologic problems, in infants of diabetic mothers, 133-135
- Hemodynamic physiology, 789-795
 - in labor and delivery, 700-702
 - monitoring of, 795-797
 - in pregnancy, 697-699
 - exercise affecting, 705-706
 - and therapeutic options, 797-805
- Hemoglobin
 - A₁ type in diabetic pregnancy, 65-71, 96
 - composition of, 1055-1056
- Hemoglobinopathies, antenatal diagnosis of, 1050, 1055-1062
 - amniotic fluid cell DNA in, 1056-1058
 - fetal blood analysis in, 1058-1061
 - and maternal screening programs, 1061-1062
- Hemolytic anemia, antenatal diagnosis of, 1064-1066
- Hemophilias, antenatal diagnosis of, 1062-1064
- Hemophilus vaginalis*. *See* Gardnerella vaginalis infection
- Hemorrhage
 - obstetric, anesthesia in, 615, 628
 - subarachnoid, in pregnancy, 832
- Hemorrhoids, in pregnancy, 758-759
- Heparin therapy in pregnancy, 814-816, 826
 - in pulmonary embolism, 770
 - in venous thrombosis, 766-767
- Hepatic vein occlusion, from oral contraceptives, 957
- Herpes simplex, cervicitis from, 420, 437
- High-risk pregnancy, obstetric anesthesia in, 671-677
- Holter monitoring, in pregnancy, 712
- Homocystinuria, collagen in, 169
- Hot flashes, in menopause, 231-239
- Hunter's syndrome, antenatal diagnosis of, 1049
- Hydergine, effects on aging, 170
- Hydramnios, in diabetic pregnancy, 98, 153
- Hydrocarbons, fetal reactions to, 853
- Hydrocephalus
 - and α -fetoprotein in amniotic fluid, 1091
 - ultrasonic diagnosis of, antenatal, 1110-1113
- Hypertension
 - from oral contraceptives, 893-895
 - in pregnancy, 781
 - and regional anesthesia use, 614
 - pulmonary, in pregnancy, 731-732, 784
- Hyperventilation, in pregnancy, 704
- Hypocalcemia, in infants of diabetic mothers, 130-133
- Hypotension
 - neonatal, 645-646
 - in pregnancy, 785
 - cerebral blood flow in, 827
 - from regional anesthesia, 603, 606
 - in supine position during labor, 528
- Hypothalamus, oral contraceptives affecting, 870-871
- Hypothyroidism, and breast cancer, 311-312
- Hysterectomy
 - abdominal, and prevention of postoperative infections, 1259-1266
 - in benign diseases, 1249-1251
 - indications for, 1245-1258
 - appropriate, 1249-1254
 - inappropriate, 1254-1255
 - in neoplastic disease, 1251-1253
 - and removal of normal uterus, 1256
 - second opinions on, 1247-1248
 - for sterilization, 1253-1254
 - vaginal vs abdominal approach in, 1255
 - vaginal vault prolapse after, repair of, 1217-1225
- Ichthyosis, antenatal diagnosis of, 1072-1075, 1080, 1084
- Immune system, age-related changes in, 171-172
- Immunizations, prior to pregnancy, 777
- Immunologic diseases, oral contraceptives affecting, 970-971
- Incisions, abdominal, 1176-1180
 - Cherny, 1179-1180
 - gridiron, 1180
 - lower midline, 1178
 - McBurney, 1180

Incisions, abdominal (*Continued*)

- muscle splitting, transverse, 1179
- paramedian, 1178-1179
- pararectus, 1179
- Pfannenstiel, 1179
- transverse, 1179-1180
- vertical, 1177-1179

Indomethacin for labor suppression, affecting infant, 676

Infants of diabetic mothers, 125-142

- birth asphyxia in, 135
- cardiomyopathy in, 139
- cardiovascular anomalies in, 153
- caudal dysplasia in, 151-152
- central nervous system anomalies in, 152
- congenital anomalies in, 42-44, 140-141, 149-156
 - incidence of, 141, 149-150
 - and mechanisms in teratogenesis, 154-156
 - and perinatal or fetal mortality, 150-151
 - types of, 151-154
- gastrointestinal anomalies in, 153
- genitourinary anomalies in, 153
- hematologic problems in, 133-135
- hyperbilirubinemia in, 133
- hypocalcemia in, 130-133
- hypoglycemia in, 125-130
 - treatment of, 129-130
- lipid metabolism in, 130
- macrosomia in, 41-42, 94, 139-140
- magnesium deficiency in, 131
- metabolic problems in, 125-133
- morphologic and functional problems in, 139-141
- nephropathy affecting, 112-113
- polycythemia in, 134-135
- prognosis of, 141-142
- renal vein thrombosis in, 135
- respiratory distress syndrome in, 136-139
 - treatment of, 138-139
- skeletal anomalies in, 151-152

Infarction, myocardial

- in diabetic pregnancy, 114-116
- from oral contraceptives, 896-897
- and protective effect of estrogen therapy, 272-275

Inhalation analgesia in obstetrics, 563-565, 620-625

- clinical uses of, 620
- drugs in, 564, 622-623
- environmental pollution from, 565, 625
- fetal safety with, 624
- maternal safety with, 623-624
- and progress of labor, 625

Inhalation analgesia in obstetrics (*Continued*)

- techniques for, 620-622

Insulin

- in amniotic fluid, in diabetic pregnancy, 96
- and breast development, 302
- plasma levels of
 - in infants of diabetic mothers, 126
 - oral contraceptives affecting, 927-928
- receptors for, in infants of diabetic mothers, 27-31, 139-140
- requirements in diabetic pregnancy, 98
- secretion of
 - aging affecting, 177
 - in diabetic pregnancy, 39-40
 - in pregnancy, 26-31
- therapy in diabetic pregnancy, 57-58, 95-96

- in intrapartum period, 61, 96-97

Intestinal anomalies, in infants of diabetic mothers, 153

Intrauterine contraceptive devices for adolescents, 982

- and *Gardnerella vaginalis* infection, 457

Iron deficiency anemia, oral contraceptives affecting, 973, 990

Isoflurane, in obstetric anesthesia, 564, 623

Isoxuprene in pregnancy, affecting infant, 676

Jaundice, in infants of diabetic mothers, 133

Ketamine, in obstetric anesthesia, 562-563, 599

- effects on neonates, 660, 661

Ketoacidosis in diabetic pregnancy, 60

- treatment of, 62-63, 97

Ketone body metabolism, in pregnancy, 34-35

Kidney

- aging affecting, 174-175
- anomalies in infants of diabetic mothers, 153
- diseases of, oral contraceptives affecting, 972-973
- nephropathy in diabetic pregnancy, 107-114
- in pregnancy, 539-540
- transplantation of, diabetic pregnancy after, 114

Koilocytes, in condylomata acuminata, 462-463, 469

Labor

- analgesia and anesthesia in, 519-677. *See also* Analgesia and anesthesia, obstetric

- in brow presentations, 346-347

- in diabetic pregnancy, 101-103

- and control of glucose levels, 60-62, 96

- in face presentations, 338-339

- hemodynamics in, 700-702

- and hypotension in supine position, 528

Labor (*Continued*)

- and prepared childbirth, 575-585. *See also* Prepared childbirth
- suppression of, affecting infant, 676-677
- Lactic acid, vaginal, 360, 365, 369
 - ratio to succinic acid, in nonspecific vaginitis, 447-448
- Lamaze method for prepared childbirth, 580-582
- Lecithin-sphingomyelin ratio in amniotic fluid, 75-78, 551-552
 - Borer modification of, 78
 - in diabetic pregnancy, 79-80, 136
 - in nephropathy, 111
- Legal liability in genetic screening, 1133-1147
- Leiomyosarcomas of vagina, 507
- Lergotril mesylate, effects on aging, 170
- Levamisole, in condylomata acuminata, 480
- Lidocaine, in obstetric analgesia, 567-568, 603, 604
 - effects on neonates, 656
- Lip, cleft, in infants of diabetic mothers, 153
- Lipid
 - in fetal cells, staining of, 74
 - metabolism of
 - in infants of diabetic mothers, 130
 - oral contraceptives affecting, 932-936
 - in pregnancy, 35-38
- Lipoprotein metabolism, in diabetic pregnancy, 40-41
- Lithium in pregnancy, affecting fetus, 858
- Liver
 - diseases of, oral contraceptives affecting, 972
 - tumors from oral contraceptives, 913-915
- Local anesthesia in obstetrics, 565-568, 587-594, 602-616. *See also* Regional anesthesia in obstetrics
- Lumbar epidural block in obstetrics, 567, 603-605. *See also* Epidural analgesia in obstetrics
- Lumbar sympathetic block in obstetrics, 567
- Lung
 - aging affecting, 174
 - fetal, 549-552, 636-637
 - corticosteroids affecting, 102, 138-139
 - development in diabetes, 84-86
 - tests for maturity of, 75-86
 - volumes in pregnancy, 534
- Lupus erythematosus
 - oral contraceptives affecting, 971
 - in pregnancy, 829
 - affecting fetus, 858
- Luteinizing hormone level
 - aging affecting, 181-182

Luteinizing hormone level (*Continued*)

- catecholamines affecting, 224
- in menopausal hot flashes, 233-234
- midcycle surge of, 194
- oophorectomy affecting, 232
- postmenopausal, 254-256
- Lymphocytes, fetal, in maternal blood, 1036
- Macrosomia, in infants of diabetic mothers, 41-42, 94, 139-140
- Magnesium deficiency, in infants of diabetic mothers, 131
- Magnesium sulfate
 - for labor suppression, affecting infant, 677
 - muscle relaxants with, 571
- Malformations
 - cardiac, from teratogenic agents, 857-859
 - in infants of diabetic mothers, 42-44, 140-141, 149-156
- Marfan's syndrome
 - cardiac disease in, 860
 - in pregnancy, 729-730, 780, 781
- McBurney incision, 1180
- Meconium aspiration syndrome, 646-647
- Medroxyprogesterone acetate, in menopausal hot flashes, 238, 267
- Melanomas of vagina, 507-508
- Mendelian disorders, cardiac disease in, 859-860
- Menkes syndrome
 - copper deficiency in, 169
 - prenatal diagnosis of, 1080
- Menopause, 163-324
 - age of, 203, 253
 - and aging process, 165-178
 - androgen levels in, 184-188
 - delayed, and breast cancer risk, 303
 - endocrinologic changes in, 254-266
 - and estrogen-induced endometrial cancer, 243-249
 - estrogen levels in, 188-190
 - estrogen replacement therapy in, 253-280
 - extraglandular estrogen formation in, 193-197
 - hot flashes in, 231-239
 - catecholamine basis for, 232, 235-237
 - estrogen therapy in, 266-267
 - pathophysiology of, 231-235
 - treatment of, 237-238
 - neuroendocrine mechanisms in, 169-170
 - osteoporosis in, 203-217
 - ovary after, 181-190
 - and postmenopausal bleeding, 285-288
 - in atrophic vaginitis, 286, 297
 - causes of, 285-289
 - cytologic studies in, 289-290

- Menopause, and postmenopausal bleeding (*Continued*)
 dilation and curettage in, 286-287, 289, 296
 endometrial biopsy in, 290-292, 295-296
 in endometrial hyperplasia, 286, 287, 292-294
 management of, 294-298
 recurrent, 292, 298
 psychologic symptoms in, 219-227
 and endocrine dysfunction, 221-227
 review questions on, 323-324
- Menorrhagia, oral contraceptives in, 989-990
- Menstrual cycle
 vaginal odors in, 365-366
 vaginal secretions in, 356-357
- Menstruation, and toxic shock syndrome, 402-404
- Meperidine, in obstetric analgesia, 597-598
 effects on neonates, 651, 652, 653, 655, 656, 657, 659, 661
- Mepivacaine, in obstetric analgesia, 567-568, 604
- Mesenteric thrombosis, from oral contraceptives, 956-957
- Mestranol, prophylactic, to prevent bone loss, 205-206
- Metabolic control of diabetic pregnancy, 51-63
- Metabolism
 in diabetic pregnancy, 38-44
 disorders in
 antenatal diagnosis of, 1041-1051
 in infants of diabetic mothers, 125-130
 in normal pregnancy, 22-38
 oral contraceptives affecting, 927-939
- Methoxyflurane, in obstetric anesthesia, 564-565, 623
 effects on neonates, 659
- Methylmalonic acidemia, antenatal diagnosis of, 1045
- Metocurine, in obstetric anesthesia, 570
- Metronidazole
 carcinogenic effects of, 456
 effects in pregnancy, 415-416, 419-420
 in *Gardnerella vaginalis* vaginitis, 374, 411, 437
 with trichomonas, 455-456
 in *Trichomonas vaginalis* vaginitis, 418-420, 437
- Metrorrhagia, oral contraceptives in, 990
- Miconazole, in candidal vulvovaginitis, 427-430, 437
- Microcephaly, ultrasonic diagnosis of, antenatal, 1113-1114
- Microflora, vaginal, 360-361, 369, 446
- Mitral valve
 prolapse in pregnancy, 724-727, 781, 827
 regurgitation in pregnancy, 724
 stenosis in pregnancy, 722-724, 780
- Monitoring, fetal, in face presentations, 342-343
- Monoamine oxidase activity, estrogen affecting, 225
- Morphine in obstetric analgesia, effects in neonates, 651-652, 656
- Mortality
 in diabetic pregnancies
 maternal, 91-92
 perinatal, 92-93, 150-151
 perinatal
 in brow presentations, 348
 in face presentations, 341-342
- Mucopolysaccharidoses, antenatal diagnosis of, 1046, 1048
- Mucorrhea, 430-432, 437
- Mucus, cervical, properties of, 356-357
- Müllerian ducts, DES exposure affecting, 381
- Multiple pregnancy. *See* Twin pregnancies
- Muscle and musculocutaneous flaps, in gynecologic surgery, 1277-1316
- Muscle relaxants, in obstetrics, 568-571
- Mycoplasmas, and pelvic inflammatory disease, 1236
- Myocardial infarction
 in diabetic pregnancy, 114-116
 from oral contraceptives, 896-897
 and protective effect of estrogen therapy, 272-275
- Myomas, uterine
 from oral contraceptives, 918
 postmenopausal bleeding in, 186
- Myometrium, estrogen in, 197-198
- Nafoxidine, in breast cancer, 314
- Naloxone, as narcotic antagonist, 600
 maternal prophylactic administration of, 660-661
 in neonates, 645
- Narcotic analgesia in obstetrics, 597-600
- Natural childbirth, 567-578
- Neonates
 of diabetic mothers, 675. *See also* Infants of diabetic mothers
 initiation of breathing in, 551, 636-637
 maternal fluid balance affecting, 674
 obstetric analgesia and anesthesia affecting, 630, 631-632, 649-667
 in high-risk pregnancy, 671-677
 long-term effects, 662-666
 short-term effects, 651-662

Neonates (*Continued*)

- parental interactions with, 654-655, 656-657
- physiology of, 545-552, 635-638
- resuscitation of, 635-647, 673. *See also* Resuscitation of newborn
- thermoregulation in, 637-638, 673-674
- Nephropathy in diabetic pregnancy, 107-114
- Netherton syndrome, prenatal diagnosis of, 1083

Neural tube defects

- in infants of diabetic mothers, 152
- prenatal diagnosis of, 1089-1102, 1121-1131

Neurobehavior of neonates, obstetric

- analgesia affecting, 631-632, 649-667

Neuroendocrine system

- in aging process, 169-171
- and psychologic symptoms in menopause, 221-227

Neurologic system, aging affecting, 177-178

Newborn. *See* Neonates

Nitrous oxide for obstetric analgesia, 622-623

Norepinephrine, as neurotransmitter, 222

Nuccal cord

- in brow presentations, 343
- in face presentations, 337

Nutrition. *See* Diet

Obesity, and binding capacity of sex hormone-binding globulin, 308-310

Obstetric analgesia and anesthesia. *See*

- Analgesia and anesthesia, obstetric

Odors, vaginal, 361-370

Omphalocele, ultrasonic diagnosis of, antenatal, 1115

Oophorectomy

- and atherosclerosis development, 273
- hot flashes after, 231, 232
- treatment of, 237-238
- and plasma levels of estrone, 257
- protective effect against breast cancer, 303-304

Oral contraceptives, 867-996

- and acids in vaginal secretions, 365
- in acne, 974, 992
- in adolescence, 982-985. *See also* Adolescent contraception
- and age of users, 958-959
- amenorrhea from 889, 915, 943-948
 - duration of, 945
 - endocrinology of, 945-946
 - factors related to, 944-945
 - progesterone challenge test in, 946
 - and responses to estrogen and clomiphene citrate, 947

Oral contraceptives, amenorrhea

from (*Continued*)

- and responses to gonadotropin releasing hormone, 946-947
- and return of ovulation or menstruation, 947-948

biologic potencies of, 885-886

breakthrough bleeding from, 888-889

and breast cancer development, 315

cerebrovascular disease from, 896, 955-956

choice of, 886-887

clinical pharmacology of, 879-887

complications from, 893-897

contraindications to, 897-899

coronary thrombosis from, 953-955

depression from, 889-890, 966

and diabetes development, 930-932

dosage of, 957-958

duration of use, 960, 988-989

in dysmenorrhea, 990-992

in endometrial hyperplasia, 917, 990

endometrium affected by, 874-875

hepatic vein occlusion from, 957

hypertension from, 893-895

hypothalamus affected by, 870-871

interaction with other drugs, 966

in iron deficiency anemia, 973, 990

mechanism of action, 869-875

in menorrhagia, 989-990

mesenteric thrombosis from, 956-957

metabolic effects of, 927-939

glucose metabolism, 927-932

lipid metabolism, 932-936

protein metabolism, 936-939

in metrorrhagia, 990

myocardial infarction from, 896-897

nausea and vomiting from, 888

and neoplasia risk, 902-923

breast disease, 907-913

cervical changes, 918-922

choriocarcinoma, 923

endometrial tumors, 915-918

investigative methods in, 904-907

liver tumors, 913-915

ovarian disease, 922-923

pituitary tumors, 915

noncontraceptive uses of, 987-992

ovaries affected by, 873

oviducts affected by, 873-874

peripheral effects of, 873-875

pharmacokinetics of, 881-884

pituitary affected by, 871-872

postcoital, 985

preparations available, 879-881

retinal vascular occlusion from, 956, 970

Oral contraceptives (*Continued*)

- review questions on, 995-996
- and screening of potential users, 899-900
- side effects of, 887-891
- smoking as risk factor with, 895, 896, 897, 959-960
- and surgical risks, 960
- systemic effects of, 966-974
 - in adolescence, 983-984
 - in central nervous system, 966-970
 - in depression, 889-890, 966
 - in endocrine disorders, 971-972
 - in epilepsy, 969
 - in eye, 956, 970
 - in gastrointestinal disorders, 972
 - in headaches, 968-969
 - in hemopoietic disorders, 973
 - in immunologic and connective tissue diseases, 970-971
 - in liver disease, 972
 - in lupus erythematosus, 971
 - in multiple sclerosis, 970
 - in renal disease, 972-973
 - in rheumatoid arthritis, 970
 - skin changes from, 973-974
 - in vaginitis, 973
 - in Wilson's disease, 968
- thromboembolism from, 895-896, 952-953
- use with medical disorders, 965-974
- vascular effects of, 951-962
 - pathogenesis of, 960-961
 - weight change from, 890-891
- Osteoporosis in menopause, 203-217
 - estrogen therapy in, 269-272
- Ovaries
 - hormones of, and breast cancer risk, 303-304
 - menopause affecting, 184-190
 - neoplasia from oral contraceptives, 922-923
 - oral contraceptives affecting, 873
 - in perimenopause, 181-184
- Oviducts, oral contraceptives affecting, 873-874
- Ovulation
 - delayed, and chromosomal abnormalities, 1035
 - and vaginal odors, 355
 - and vaginal secretions, 357
- Oxytocin
 - challenge test in diabetic pregnancy, 99
 - effects on neonates, 675
- Pain, obstetric, mechanisms in, 576-577, 579, 580-581, 601-602
- Palate, cleft, in infants of diabetic mothers, 153
- Pancuronium, in obstetric anesthesia, 570
- Papillomavirus infection, vaginal, 461-481

- Paracervical block in obstetrics, 567, 588-591
 - fetal complications from, 590-591
 - maternal complications from, 589-590
 - technique of, 588-589
- Parathyroid gland, function studies in infants of diabetic mothers, 131
- Parity
 - and brow presentations, 344
 - and face presentations, 334-335
- Pelvic inflammatory disease
 - in actinomycosis, 1236-1237
 - anaerobic and aerobic bacteria in, 1232-1235
 - Chlamydia trachomatis* in, 1235-1236
 - epidemiology of, 1230-1232
 - hysterectomy in, 1231
 - incidence of, 1230
 - late sequelae of, 1231-1241
 - and management of pelvic abscess, 1187-1196
 - mycoplasmas in, 1230
 - nongonococcal pathogens in, 1232-1238
 - problems in studies of, 1228-1230
 - in streptococcal infections, 1237-1238
 - treatment of, 1238-1240
 - in tuberculosis, 1237
- Pelvic size
 - and brow presentations, 345
 - and face presentations, 335-336
- Pelvimetry, x-ray
 - in brow presentations, 348
 - in face presentations, 340-341
- Pentobarbital, in obstetric analgesia, affecting neonates, 652
- Pericardial effusions, in pregnancy, 737
- Pfannenstiel incision, 1179
- pH, vaginal, 360
 - and malodor formation, 373-374
 - in vaginitis, 374, 450
- Phenothiazines, in obstetric analgesia, 599
 - effects on neonates, 656, 657
- Phenylketonuria
 - antenatal diagnosis of, 1045-1046
 - maternal, affecting fetus, 858
- Pheochromocytoma, hot flashes with, 232, 235
- Phlebography, in venous thrombosis of pregnancy, 765
- Phonocardiography, in pregnancy, 712-714
- Phosphatidylcholine in amniotic fluid, and fetal lung maturity, 86, 111
- Phosphatidylglycerol in amniotic fluid, 80-84, 136
- Photocoagulation, in diabetic pregnancy with retinopathy, 120
- Photosensitivity, from oral contraceptives, 974

Pituitary gland

- ablation in diabetic pregnancy with retinopathy, 120
- hormone changes in aging, 175-176
- oral contraceptives affecting, 871-872, 971-972
- tumors from oral contraceptives, 915

Placenta

- and circulation in fetus, 545-547
- previa, and face presentations, 336
- transfer of drugs in, 555-558

Plasma volume in pregnancy, 526, 693-697

Plethysmography, in venous thrombosis of pregnancy, 766

Podophyllin, in condylomata acuminata, 479-480

Polycythemia, in infants of diabetic mothers, 134-135

Polyhydramnios, and face presentations, 336

Pompe's disease, antenatal diagnosis of, 1047, 1049

Porphyria, oral contraceptives affecting, 974

Posture, and cardiac output at term, 528-529

Prednisone provocative test, for glucose intolerance in pregnancy, 14-15

Pregnancy

- in adolescence, hazards of, 979-980
- angina pectoris in, 785
- antenatal diagnosis of genetic disorders in.

- See* Antenatal diagnosis of disorders

- anticoagulant drugs in, 813-816, 826

- in pulmonary embolism, 770

- in venous thrombosis, 766-767

- aortic disorders in, 729-731

- aortic valve disorders in, 727-730, 780

- arrhythmias in, 782-783

- treatment of, 809-813

- atrial septal defect in, 732-734

- blood flow in

- regional, 533

- renal, 533, 539

- uterine, 530-533, 556

- blood pressure in, 529, 699

- blood volume in, 526, 693-697

- cardiac output in, 526-529, 697-699

- distribution of, 702-703

- exercise affecting, 705-706

- cardiomyopathy in, 737, 781

- cardiovascular diseases in, 691-865. *See also*

- Cardiovascular disorders, in pregnancy

- cardiovascular physiology in, 693-707

- condylomata acuminata in, 481

- diabetes in, 1-162, 675. *See also* Diabetic pregnancy

Pregnancy (*Continued*)

- digitalis glycosides in, 817-818

- diuretics in, 818-820

- ectopic, hysterectomy in, 1251

- and effects of metronidazole, 415-416, 419-420

- Eisenmenger syndrome in, 732

- endocarditis in, subacute bacterial, 734-735, 784, 828

- exercise in, 704-707

- and fetal health, 706-707

- fat mobilization in, 34-35

- gastrointestinal changes in, 538-539

- glucagon secretion in, 31-32

- glucose assimilation in, 32-34

- heart in, 525-526

- heart failure in, 783-784

- hemorrhoids in, 758-759

- high-risk, obstetric anesthesia in, 671-677

- hypertension in, 781

- pulmonary hypertension, 731-732, 784

- hypotension in, 785

- insulin secretion and insulin response in, 26-31

- lipoprotein lipid metabolism in, 35-38

- Marfan's syndrome in, 729-730, 780, 781

- metabolic changes in, 22-38

- mitral valve disorders in, 722-727, 780

- patent ductus arteriosus in, 735

- pericardial effusions in, 737

- physiologic changes in, 525-540

- and preparation for childbirth, 575-585

- and prosthetic heart valve function, 735, 737, 780

- pulmonary embolism in, 762, 769-770

- pulmonary stenosis in, 731

- renal changes in, 539-540

- respiration in, 703-704

- exercise affecting, 704-705

- respiratory changes in, 533-538

- spider veins in, 759

- strokes in, 825-832. *See also* Cerebrovascular disease, in pregnancy

- subaortic stenosis in, idiopathic hypertrophic, 735-736, 781-782

- tetralogy of Fallot in, 732

- thromboembolic complications of, 784

- varicose veins in, 749-758, 764

- vascular resistance in, 699

- venous disorders in, 749-759

- venous dynamics in, 743-749

- venous thrombosis in, 761-768

- ventricular septal defect in, 734

- weight gain and adipose tissue metabolism in, 22-26

- Premature delivery
 - extreme, management of, 677
 - general anesthesia in, 629
 - regional anesthesia in, 614
- Prenatal diagnosis. *See* Antenatal diagnosis of disorders
- Prepared childbirth, 575-585
 - educational materials for, 584-585
 - effectiveness of, 582-583
 - Lamaze method in, 580-582
 - psychoprophylaxis in, 578-580
 - effect on neonates, 652
 - Read method of natural childbirth in, 576-578
- Presentation
 - breech, analgesia in, 523
 - face and brow, 333-349
- Procainamide, in arrhythmias in pregnancy, 811
- Progesterone
 - challenge test in amenorrhea, 946
 - and estrogen production, 199-200
 - receptors for, 199
 - in breast cancer, 313
 - respiratory effects of, 534, 564
- Progestins
 - and estrogen production, 199-200
 - with estrogen replacement therapy, 213, 248
 - in menopausal hot flashes, 238
 - in oral contraceptives. *See* Oral contraceptives
- Prolactin levels, in breast cancer, 311
- Promethazine in obstetric analgesia,
 - affecting neonates, 652, 657, 659
- Propranolol, in arrhythmias in pregnancy, 812-813
 - affecting fetus, 677, 858
- Prostaglandins, and neuroendocrine function, 225-226
- Prosthetic heart valves, function in pregnancy, 735, 737, 780
- Protein
 - excretion in pregnancy, 539
 - metabolism of, oral contraceptives affecting, 936-939
 - in vaginal secretions, 357-359
- Proteinuria, in diabetic nephropathy in pregnancy, 110
- Psychologic symptoms, in menopause, 219-227
 - and endocrine dysfunction, 221-227
- Psychoprophylaxis, in prepared childbirth, 578-580
 - effects on neonates, 652
- Pudendal block, in obstetrics, 567, 592-594
 - fetal complications from, 593
 - maternal complications from, 593
 - technique of, 592-593
- Pudendal varicosities, in pregnancy, 758
- Pulmonary artery catheter, for hemodynamic monitoring, 795-797
- Pulmonary embolism, in pregnancy, 762, 769-770
- Pulmonary hypertension, in pregnancy, 731-732, 784
- Pulmonic valve stenosis, in pregnancy, 731
- Purpura, thrombotic thrombocytopenic, in pregnancy, 829-830
- Putrescine, in vaginal discharge, 374, 448, 449
- Pyelonephritis, in diabetic pregnancy, 98
- Quinidine, in arrhythmias in pregnancy, 811
- Radiation exposure, breast cancer from, 306
- Radiology
 - chest x-ray in pregnancy, 712
 - as fetal maturity test, 74
- Radionuclide studies
 - cardiac, in pregnancy, 718-721
 - in venous thrombosis of pregnancy, 766
- Radiotherapy
 - and antenatal diagnosis of fetal disorders, 1034
 - in invasive carcinoma of vagina, 511-512
- Rectus femoris muscle flap transposition, 1291-1292
- Refsum's disease, prenatal diagnosis of, 1084
- Regional anesthesia in obstetrics, 565-568, 587-594, 602-616
 - in abnormal patients, 613-616
 - complications from, 606-613
 - in diabetes, 615
 - effects on labor, 611-612
 - effects on neonates, 656
 - failure of, 609-611
 - in fetal distress, 614
 - headache from, 607
 - in heart disease, 615-616
 - in hemorrhage, 615
 - in hypertension, 614
 - hypotension from, 603, 606
 - neurologic disorders from, 613
 - in prematurity, 614
 - respiratory insufficiency from, 606-607
 - techniques with, 602-606
 - in toxemia, 613-614
 - toxic reactions to, 607-608
- Renal vein thrombosis, in infants of diabetic mothers, 135
- Respiration, in pregnancy, 703-704
 - exercise affecting, 704-705

- Respiratory distress syndrome, in infants of diabetic mothers, 136-139
treatment of, 138-139
- Respiratory system
fetal, 549-552, 636-637
drugs affecting, 672
insufficiency from regional anesthesia, 606-607
in pregnancy, 533-538
- Resuscitation of newborn, 635-647, 673
and Apgar scoring system, 640-643
and causes of neonatal depression, 639-640
drug therapy in, 644-645
equipment for, 643-644
in hypotension, 645-646
in meconium aspiration, 646-647
principles of, 640
- Retinal vascular occlusion, from oral contraceptives, 956
- Retinopathy, in diabetic pregnancy, 116-121
nephropathy with, 110
- Rh sensitization, as amniocentesis risk, 1013-1015
- Rheumatoid arthritis, oral contraceptives affecting, 970
- Ritodrine in pregnancy, affecting infant, 676
- Rubella in pregnancy, affecting fetus, 858, 859
- Sacropexy, abdominal, for vaginal vault prolapse, 1217-1225
- Sarcoma of vagina, 507
- Sartorius muscle flap transposition, 1280
- Sclerosis, multiple, oral contraceptives affecting, 970
- Scopolamine, in obstetric analgesia, 571, 599
- Secobarbital for obstetric analgesia, affecting neonates, 653, 656, 657
- Semen, affecting vaginal odor, 374
- Serotonin
metabolism affected by estrogens, 225
as neurotransmitter, 222
- Sex hormone-binding globulin
estradiol bound to, 188
mestranol affecting, 211
plasma levels in breast cancer, 308-310
testosterone bound to, 186
- Sex hormones in pregnancy, affecting fetus, 858
- Sexual activity
in adolescence, 977-979
vaginal fluid composition in, 370-373
- Shake test of amniotic fluid, 78-79
- Sickle cell disease
antenatal diagnosis of, 1060
oral contraceptives affecting, 973
in pregnancy, 829
screening program for, 1061-1062
- Sjogren-Larsson syndrome, prenatal diagnosis of, 1080
- Skeletal system
anomalies in infants of diabetic mothers, 151-152
bone loss in menopause, 203-217
estrogen therapy in, 269-272
changes with age, 173
ultrasonic diagnosis of anomalies, antenatal, 1118
- Skin
changes from oral contraceptives, 973-974
hereditary disorders of, prenatal diagnosis of, 1069-1086
- Skin sampling, fetal, 1072-1079
- Smoking, and effects of oral contraceptives, 895, 896, 897, 959-960
- Sodium levels, maternal, affecting infant, 674
- Sphingomyelin ratio to lecithin, in amniotic fluid, 75-78, 551-552
- Spider veins, in pregnancy, 759
- Spina bifida
and α -fetoprotein in amniotic fluid, 1089-1091
ultrasonic diagnosis of, antenatal, 1109
- Spinal anesthesia in obstetrics, 567, 602-603
effects on labor, 611-612
effects on neonates, 661, 662
failure of, 609
neurologic complications from, 613
- Sterilization, hysterectomy in, 1253-1254
- Steroid hormones, in amniotic fluid, 1046
- Streptococcal infections, and pelvic inflammatory disease, 1237-1238
- Streptokinase in pregnancy
in pulmonary embolism, 770
in venous thrombosis, 767-768
- Strokes. *See* Cerebrovascular disease
- Subaortic stenosis, idiopathic hypertrophic, in pregnancy, 735-736, 781-782
- Subarachnoid hemorrhage, in pregnancy, 832
- Succinic acid ratio to lactic acid, in vaginitis, 447-448
- Succinylcholine, in obstetric anesthesia, 570
- Sulfonamide cream, in *Gardnerella vaginalis* infection, 454-455
- Surfactant, pulmonary, in test for fetal maturity, 78
- Surgery
abdominal incisions in, 1176-1180
transverse, 1179-1180
vertical, 1177-1179
cesarean section. *See* Cesarean section
and indications for hysterectomy, 1245-1258. *See also* Hysterectomy
intraoperative considerations in, 1180-1181

Surgery (Continued)

- muscle and musculocutaneous flaps in, 1277-1316
 - gracilis, 1280-1282
 - principles of, 1278-1279
 - rectus femoris, 1291-1292
 - sartorius, 1280
 - tensor fascia lata, 1282-1291
- and pelvic abscess management, 1187-1196
- preparation of patient for, 1175-1176
- in pulmonary embolism of pregnancy, 770
- and risks from oral contraceptives, 960
- sacropepy for vaginal vault prolapse, 1217-1225
- suture material in, 1181-1183
- urinary tract injuries in, 1267-1276
- uterine unification procedures, 1199-1214
- in venous thrombosis of pregnancy, 768
- wound closure in, 1181-1183
- wound dehiscence in, 1184
- Suture material, in gynecologic surgery, 1181-1183
- Sympathetic block, lumbar, in obstetrics, 567
- Takayasu's disease, in pregnancy, 829
- Tamoxifen, in breast cancer, 314
- Tampons
 - and toxic shock syndrome, 402-404
 - vaginal mucosal alterations from, 396-402
 - vaginal ulcers from, 395-396
- Tay-Sachs disease, antenatal diagnosis of, 1047, 1049
- Temperature of body
 - in menopausal hot flashes, 233
 - neonatal regulation of, 637-638, 673-674
- Tensor fascia lata muscle flap transposition, 1282-1291
- Teratogenic agents, cardiac malformations from, 857-859
- Teratogenic risk, in infants of diabetic mothers, 42-44, 140-141, 149-156
- Testosterone
 - aging affecting levels of
 - in females, 186-187
 - in males, 176-177
 - conversion to estradiol, 189, 194
 - postmenopausal secretion of, 257
- Tetracaine, for spinal anesthesia, 567, 603
 - effects on neonates, 661, 662
- Tetracycline, in *Gardnerella vaginalis* infection, 455
- Tetralogy of Fallot, in pregnancy, 732
- Thalassemia
 - antenatal diagnosis of, 1050, 1056-1057
 - screening program for, 1061-1062
- Thermoregulation, neonatal, 637-638, 673-674

- Thiazide diuretics, in pregnancy, 818-820
- Thiopental, in obstetric anesthesia, 561-562
 - effects on neonates, 660, 661
- Thrombocytopenic purpura, thrombotic, in pregnancy, 829-830
- Thromboembolism
 - development after estrogen therapy, 276-277
 - from oral contraceptives, 895-896, 952-953
 - in pregnancy, 784
- Thrombolytic therapy in pregnancy
 - in pulmonary embolism, 770
 - in venous thrombosis, 767-768
- Thrombosis, venous
 - in pregnancy, 761-768, 784
 - cerebral vein, 830-831
 - diagnosis of, 765-766
 - epidemiology of, 761-763
 - pathophysiology of, 763-765
 - phlebography in, 765
 - plethysmography in, 766
 - prophylaxis in, 768
 - radioiodine-labeled fibrinogen scanning in, 766
 - treatment of, 766-768
 - ultrasonography in, 765-766
 - of renal vein, in infants of diabetic mothers, 135
- Thymus, and aging of immune system, 171
- Thyroid disease, oral contraceptives affecting, 971
- Thyroid hormones
 - activity in aging, 175
 - in amniotic fluid, 1046
 - and breast cancer, 311-312
- Thyroxine, and breast development, 302
- Tocolytic agents, affecting infant, 676-677
- Toxemia of pregnancy
 - general anesthesia in, 628-629
 - regional anesthesia in, 613-614
- Toxic shock syndrome, 402-404
- Transplantation of kidney, diabetic pregnancy after, 114
- Trichomonas vaginalis*
 - cervicitis from, 420, 437
 - vaginitis from, 412-420, 455-456
 - clinical features of, 412-416
 - diagnosis of, 416-418
 - treatment of, 418-420, 437
- Trichothiodystrophy, prenatal diagnosis of, 1083
- Triglyceride metabolism
 - oral contraceptives affecting, 933
 - in pregnancy, 35-38
 - in diabetic pregnancy, 40-41

- Trisomy syndromes
 antenatal diagnosis of Down's syndrome, 1025-1029
 cardiac disease in, 859
- Trophoblastic disease, hysterectomy in, 1252
- Tryptophan metabolism, 224
 estrogens affecting, 225
- Tuberculosis, pelvic inflammatory disease in, 1237
- Tuberous sclerosis, prenatal diagnosis of, 1086
- d*-Tubocurarine, in obstetric anesthesia, 570
- Tumors
 of breast. *See* Breast, cancer of
 cervical cancer
 hysterectomy in, 1251-1252
 postmenopausal bleeding in, 286, 287
 choriocarcinoma
 cerebral metastases in, 830
 oral contraceptives affecting, 923
 endometrial. *See* Endometrium, carcinoma of
 from oral contraceptives, 903-923
 uterine
 hysterectomy in, 1250, 1251-1252
 and postmenopausal bleeding, 286, 287, 290, 296
 vaginal
 carcinoma in situ, 485-498
 invasive tumors, 503-514
- Twin pregnancies
 amniocentesis in, 1016-1017
 delivery of, analgesia and anesthesia in, 523
 in diabetic pregnancy, 153
- Ulcers, vaginal, 408
 from tampons, 395-396
- Ultrasonography
 fetal
 and amniocentesis, 1009, 1015-1016, 1106-1108
 in anencephaly, 1110
 in antenatal diagnosis of defects, 1093, 1103-1120
 for cardiac anatomy, 837-842
 in diabetic pregnancy, 100
 and α -fetoprotein in maternal serum, 1103-1106
 in gastrointestinal anomalies, 1114-1116
 in hydrocephalus, 1110-1113
 for maturity assessment, 75
 in microcephaly, 1113-1114
 in skeletal dysplasia, 1118
 in spina bifida, 1109
 in urinary tract disorders, 1116-1118
 for vascular dynamics, 842-847
 in pregnancy
 in cardiac disorders, 714-718, 786
 in venous thrombosis, 765-766
- Umbilical arteries
 blood velocity waveforms from, 845-847
 single, in infants of diabetic mothers, 153
- Urea, in vaginal fluids, 369, 371
- Urethra, atrophic changes in menopause, estrogen therapy in, 268-269
- Urinary tract
 infections from oral contraceptives, 972-973
 operative injuries to, 1267-1276
 anatomic factors in, 1267-1271
 in bladder, 1275-1276
 management of, 1274-1276
 prevention of, 1271-1272
 ureteral, 1273-1274
 ultrasonic diagnosis of disorders, antenatal, 1116-1118
- Urokinase in pregnancy
 in pulmonary embolism, 770
 in venous thrombosis, 767-768
- Urticaria, oral contraceptives affecting, 971
- Uterus
 abnormalities from DES exposure, 381-386
 blood flow in pregnancy, 530-533, 556
 cervical changes from oral contraceptives, 918-922
 cervical mucus affected by oral contraceptives, 873
 cervicitis, 420-424
 dilation and curettage of, in postmenopausal bleeding, 286-287, 289, 296
 dysfunctional bleeding in, estrogen therapy in, 275
 endometrial hyperplasia of. *See* Endometrium, hyperplasia of
 endometrial tumors from oral contraceptives, 915-918
 endometrium affected by oral contraceptives, 874-875
 estrogen in endometrium, 197-200
 indications for hysterectomy, 1245-1258.
 See also Hysterectomy
 relaxation from general anesthesia, 627
 tumors of, and postmenopausal bleeding, 286
 unification procedures, 1199-1214
- Vaccine therapy, in condylomata acuminata, 480
- Vagina
 adenocarcinoma of, 506-507
 from DES exposure, 386-388
 adenosis of
 and carcinoma in situ, 495
 from DES exposure, 381
 anaerobic organisms in, 361
 in nonspecific vaginitis, 446-447
 artificial, transudate production in, 371

Vagina (Continued)

- atrophy in menopause
 - bleeding with, 286, 297
 - estrogen therapy in, 267-268
- carcinoma in situ, 485-498
 - histopathology in, 488-490, 496
 - incidence of, 486
 - pathogenesis of, 486-487
 - pathology of, 487-490
 - symptoms of, 487
 - treatment of, 490-495
- cellular desquamation from, 357
- condylomata acuminata of, 461-481
- DES-related lesions of, 379-393. *See also*
 - Diethylstilbestrol exposure in utero
- discharge from
 - infections with, 407-437
 - mucoid or epithelial, 430-432, 437
 - endodermal sinus tumors of, 507
 - endometriosis of, 495
 - fistulas of, 408
 - invasive tumors of, 503-514
 - diagnosis of, 508-511
 - pathology of, 504-508
 - treatment of, 511-514
 - lymphatic drainage of, 505-506
 - melanomas of, 507-508
 - microbiology of, 360-361, 369, 446
 - mucorrhea in, 430-432, 437
 - odors from, 361-370
 - cyclic variations in, 365-366
 - malodors, 373-375
 - as sexual attractants, 363, 365
 - sexual stimulation affecting, 370-373
 - in vaginitis, 374-375, 448, 450
- pH of, 360
 - and malodor formation, 373-374
 - in vaginitis, 374, 450
- sarcoma of, 507
- secretions of, 355-375
 - aliphatic acids in, 364, 447
 - amines in, in nonspecific vaginitis, 448
 - amino acids and proteins in, 357-359
 - cadaverine in, 448, 449
 - carbohydrates in, 359-360
 - cyclic changes in, 356-357
 - excessive, 430-432
 - glycogen in, 360, 369
 - high molecular weight constituents of, 356-357
 - lactic acid in, 360, 365, 369, 447
 - low molecular weight compounds in, 361-370
 - organic constituents of, 364-366
 - putrescine in, 374, 448, 449

Vagina, secretions of (Continued)

- quantitation of, 355-356
- sexual stimulation affecting, 370-373
- succinic acid in, in nonspecific vaginitis, 447-448
- tampons affecting, 395-405
- ulcers of, 408
 - from tampons, 395-396
- vault prolapse in, repair of, 1217-1225
- Vaginectomy, in carcinoma in situ, 491
- Vaginitis, 407-437
 - atrophic, 407, 432-434
 - clinical features of, 432-433
 - diagnosis of, 433
 - treatment of, 433-434, 437
 - in candidiasis, 424-430
 - desquamative inflammatory, 408
 - treatment of, 437
 - emphysematosa, 408
 - treatment of, 437
 - in *Gardnerella vaginalis* infection, 374, 407, 411-412, 439-458
 - nonspecific, 439-458
 - oral contraceptives affecting, 973
 - treatment of, 434-437
 - in *Trichomonas vaginalis* infection, 412-420
 - vaginal odor in, 374-375, 448, 450
- Vaporizers, for inhalation analgesia, 620-621
- Varicose veins in pregnancy, 749-758, 764
 - complications of, 757-758
 - treatment of, 754-757
 - vulvar and pudendal, 758
- Vasculature
 - disease of, in diabetic pregnancy, 107-121
 - fetal dynamics in, ultrasonographic evaluation of, 842-847
 - oral contraceptives affecting, 951-962
 - in pregnancy, 533
 - resistance in, 699
 - pulmonary, in fetus, 548, 636
 - drugs affecting, 672
 - uterine, in pregnancy, 532
- Vectorcardiography in pregnancy, 712
- Venous disorders in pregnancy, 749-759
 - thrombosis, 761-768, 784
- Venous dynamics in pregnancy, 743-749
- Ventricular septal defect, in pregnancy, 734
- Vinbarbital in obstetric analgesia, affecting neonates, 651-652
- Virus infections
 - cervicitis from herpes simplex, 420, 437
 - vaginal condylomata acuminata, 461-481
- Viscosity of blood, in infants of diabetic mothers, 134
- Vitamin D metabolites, in infants of diabetic mothers, 133

Vulva

- atrophic changes in menopause, estrogen therapy in, 267-268
- varicosities in pregnancy, 758

Vulvovaginitis

- in candidiasis, 424-430
- vaginal odor in, 374

Warfarin in pregnancy

- affecting fetus, 826, 858
- contraindications to, 784
- in venous thrombosis, 767

Weight

- changes in diabetic pregnancy, 38-39

Weight (*Continued*)

- changes from oral contraceptives, 890-891
- gain in pregnancy, 22-26
- macrosomia in infants of diabetic mothers, 41-42, 94, 139-140
- obesity, and binding capacity of sex hormone-binding globulin, 308-310
- Wilson's disease, oral contraceptives affecting, 968
- Wiskott-Aldrich syndrome, prenatal diagnosis of, 1082
- Xeroderma pigmentosum, antenatal diagnosis of, 1032, 1081

